In the context of liver cancer, eIF6 genetic reduction affects the incidence and size of surface HCC nodules in mouse models of NAFLD/NASH rapid progression into HCC and blocks the in vitro growth of HCC spheroids. This evidence concerns the gene EIF6 and metabolic dysfunction-associated steatohepatitis.